Clinical Trial

Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study evaluated the safety and efficacy of SPH4336 in combination with endocrine therapy in breast cancer Patients with brain metastases.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2023-05-14; most recent amendment 2026-04-29.
Status change: Not Yet Recruiting → Recruiting 2023-12-13
Trial Details
NCT Number NCT05872347
Lead Sponsor Shanghai Pharmaceuticals Holding Co., Ltd
Conditions Breast Cancer Brain Metastases
Enrollment 52 participants
Start Date 2023-09-19
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-05